Neal Joseph M
From the Virginia Mason Medical Center, Seattle, WA.
Reg Anesth Pain Med. 2016 Mar-Apr;41(2):195-204. doi: 10.1097/AAP.0000000000000295.
In 2010, the American Society of Regional Anesthesia and Pain Medicine's evidence-based medicine assessment of ultrasound (US)-guided regional anesthesia (UGRA) analyzed the effect of this nerve localization technology on patient safety. That analysis focused on 4 important regional anesthesia complications: peripheral nerve injury, local anesthetic systemic toxicity (LAST), hemidiaphragmatic paresis (HDP), and pneumothorax. In the intervening 5 years, further research has allowed us to refine our original conclusions. This update reviews previous findings and critically evaluates new literature published since late 2009 that compares the patient safety attributes of UGRA with those of traditional nerve localization methods. As with the previous version of this exercise, analysis focused on randomized controlled trials that compared UGRA with an alternative neural localization method and case series of more than 500 patients. The Jadad score was used to grade individual study quality, and conclusions were graded as to strength of evidence. Of those randomized controlled trials identified by our search techniques, 28 compared the incidence of postoperative nerve symptoms, 27 assessed LAST parameters, 7 studied HDP, and 9 reported the incidence of pneumothorax. The current analysis strengthens our original conclusions that US guidance has no significant effect on the incidence of postoperative neurologic symptoms and that UGRA reduces the incidence and intensity of HDP but does so in an unpredictable manner. Conversely, emerging evidence supports the effectiveness of US guidance for reducing LAST across its clinical presentation continuum. The predicted frequency of pneumothorax has grown smaller in tandem with increased experience with US-guided supraclavicular block. This evidence-based review summarizes both the power and the limitations of UGRA as a tool for improving patient safety.
WHAT'S NEW: Since the original 2010 publication of this analysis, evidence has continued to support the concept that ultrasound (US) guidance does not meaningfully affect the incidence of peripheral nerve injury (PNI) associated with regional anesthesia. Similar confirmatory evidence attests to US guidance reducing the incidence and intensity of hemidiaphragmatic paresis (HDP) but not eliminating it. Literature published since late 2009 reports the effective role of US guidance in reducing the incidence of local anesthetic systemic toxicity and allows calculation of a lower predicted frequency of pneumothorax associated with US-guided supraclavicular blocks.
2010年,美国区域麻醉与疼痛医学学会对超声(US)引导下区域麻醉(UGRA)进行的循证医学评估分析了这种神经定位技术对患者安全的影响。该分析聚焦于4种重要的区域麻醉并发症:周围神经损伤、局麻药全身毒性反应(LAST)、半膈肌麻痹(HDP)和气胸。在随后的5年里,进一步的研究使我们能够完善最初的结论。本更新回顾了先前的研究结果,并严格评估了自2009年末以来发表的将UGRA与传统神经定位方法的患者安全属性进行比较的新文献。与本研究的上一版本一样,分析聚焦于比较UGRA与另一种神经定位方法的随机对照试验以及超过500例患者的病例系列。采用Jadad评分对各个研究的质量进行分级,并根据证据强度对结论进行分级。在通过我们的检索技术确定的那些随机对照试验中,28项比较了术后神经症状的发生率,27项评估了LAST参数,7项研究了HDP,9项报告了气胸的发生率。当前的分析强化了我们最初的结论,即超声引导对术后神经症状的发生率没有显著影响,并且UGRA可降低HDP的发生率和严重程度,但方式不可预测。相反,新出现的证据支持超声引导在整个临床表现连续体中降低LAST发生率的有效性。随着超声引导下锁骨上阻滞经验的增加,气胸的预测发生率已降低。本循证综述总结了UGRA作为一种改善患者安全的工具的优势和局限性。
自2010年首次发表该分析以来,证据继续支持超声(US)引导不会显著影响与区域麻醉相关的周围神经损伤(PNI)发生率这一概念。类似的确证性证据证明超声引导可降低半膈肌麻痹(HDP)的发生率和严重程度,但并不能消除它。自2009年末以来发表的文献报道了超声引导在降低局麻药全身毒性反应发生率方面的有效作用,并允许计算与超声引导下锁骨上阻滞相关的较低气胸预测发生率。